VivoSim Labs, INC.
Financial highlights
| Metric | FY 03/31/25 | FY 12/31/24 | FY 03/31/24 | FY 03/31/23 | FY 03/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $144,000 | — | $109,000 | $370,000 | $1.5M |
| Cost of revenue | $5,000 | — | — | — | — |
| Selling, general & administrative | $7.7M | — | $9.7M | $9.2M | $9.7M |
| Research and development | $5.0M | — | $5.5M | $8.9M | $3.3M |
| Operating income | -$12.6M | — | -$15.1M | -$17.7M | -$11.5M |
| Interest expense | $10,000 | — | — | — | — |
| Income tax expense | $2,000 | — | $2,000 | $2,000 | $2,000 |
| Net income | -$2.5M | — | -$14.7M | -$17.3M | -$11.4M |
| Balance Sheet | |||||
| Cash and equivalents | $11.3M | — | $2.9M | $15.3M | $28.7M |
| Current assets | $12.1M | — | $3.9M | $17.0M | $29.5M |
| Total assets | $14.7M | — | $6.3M | $20.3M | $33.3M |
| Current liabilities | $3.7M | — | $1.9M | $3.7M | $1.4M |
| Total liabilities | $4.2M | — | $2.7M | $5.0M | $3.1M |
| Stockholders' equity | $10.5M | $364,000 | $3.6M | $15.3M | $30.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$9.5M | — | -$14.7M | -$12.4M | -$8.5M |
| Depreciation and amortization | $266,000 | — | $280,000 | $293,000 | $142,000 |
| Stock-based compensation | $532,000 | — | $1.5M | $2.4M | $2.3M |
| Capital expenditure | $13,000 | — | $42,000 | $396,000 | $409,000 |
| Free cash flow | -$9.5M | — | -$14.7M | -$12.8M | -$8.9M |
| Share repurchases | — | — | — | — | $0 |
| Impairments | $0 | — | $0 | $0 | $0 |
Shares outstanding 2.6M · Free float 97.5%
Annual filing data through FY ended March 31, 2025; float as of July 13, 2026.